Vorinostat

CHF 48.00
In stock
SYN-3006-M0055 mgCHF 48.00
SYN-3006-M01010 mgCHF 60.00
SYN-3006-M05050 mgCHF 84.00
SYN-3006-M100100 mgCHF 108.00
 
More Information
Product Details
Synonyms SAHA; Suberoyl anilide bishydroxamide; Suberoylanilide hydroxamic acid;
Product Type Chemical
Properties
Formula C14H20N2O3
MW 264.3
CAS 149647-78-9
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol. Almost insoluble in water.
Identity Determined by 1H-NMR.
Declaration Manufactured by SynKinase.
Other Product Data Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key WAEXFXRVDQXREF-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Vorinostat (SAHA, MK0683, Zolinza) inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized.
Product References
  1. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci: A. Munshi, et al.; Mol. Cancer Ther. 5, 1967 (2006)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.